Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ovarian Neoplasms | 57 | 2024 | 4900 | 2.920 |
Why?
|
Peritoneal Neoplasms | 12 | 2024 | 703 | 1.190 |
Why?
|
Endometrial Neoplasms | 10 | 2021 | 1378 | 1.130 |
Why?
|
Neoplastic Syndromes, Hereditary | 2 | 2019 | 248 | 0.920 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 33 | 2020 | 11868 | 0.910 |
Why?
|
Genital Neoplasms, Female | 5 | 2023 | 533 | 0.830 |
Why?
|
Neoplasm Recurrence, Local | 26 | 2020 | 9373 | 0.810 |
Why?
|
Taxoids | 10 | 2013 | 665 | 0.750 |
Why?
|
Paclitaxel | 20 | 2014 | 1728 | 0.700 |
Why?
|
Gynecologic Surgical Procedures | 5 | 2014 | 287 | 0.670 |
Why?
|
Diaphragm | 5 | 2013 | 356 | 0.640 |
Why?
|
Cystadenocarcinoma, Serous | 4 | 2024 | 479 | 0.630 |
Why?
|
Vulvar Neoplasms | 4 | 2022 | 270 | 0.580 |
Why?
|
Neoplasm Staging | 31 | 2024 | 11206 | 0.530 |
Why?
|
Neoplasms, Glandular and Epithelial | 6 | 2015 | 488 | 0.530 |
Why?
|
Fallopian Tube Neoplasms | 7 | 2024 | 326 | 0.520 |
Why?
|
Antineoplastic Agents, Phytogenic | 6 | 2000 | 616 | 0.490 |
Why?
|
Pelvic Exenteration | 3 | 2014 | 22 | 0.480 |
Why?
|
Antineoplastic Agents | 22 | 2016 | 13648 | 0.470 |
Why?
|
Camptothecin | 3 | 2004 | 600 | 0.450 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2016 | 258 | 0.430 |
Why?
|
Neoplasm, Residual | 4 | 2014 | 1009 | 0.420 |
Why?
|
Angiogenesis Inhibitors | 4 | 2015 | 2056 | 0.420 |
Why?
|
Uterine Cervical Neoplasms | 8 | 2020 | 2047 | 0.380 |
Why?
|
Laparotomy | 2 | 2016 | 460 | 0.340 |
Why?
|
Carboplatin | 11 | 2014 | 789 | 0.340 |
Why?
|
Neoadjuvant Therapy | 4 | 2023 | 2895 | 0.330 |
Why?
|
Drug Administration Schedule | 21 | 2013 | 4850 | 0.320 |
Why?
|
Lymph Node Excision | 7 | 2022 | 1259 | 0.310 |
Why?
|
Female | 119 | 2024 | 396112 | 0.300 |
Why?
|
Risk Reduction Behavior | 1 | 2014 | 1123 | 0.290 |
Why?
|
Molecular Targeted Therapy | 2 | 2020 | 2822 | 0.290 |
Why?
|
Surgical Procedures, Operative | 1 | 2019 | 1941 | 0.290 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 11 | 2001 | 5389 | 0.290 |
Why?
|
Genetic Predisposition to Disease | 3 | 2020 | 18071 | 0.280 |
Why?
|
Hysterectomy | 5 | 2021 | 864 | 0.280 |
Why?
|
Uterine Neoplasms | 3 | 2024 | 1421 | 0.280 |
Why?
|
Dacarbazine | 2 | 2006 | 552 | 0.280 |
Why?
|
Middle Aged | 87 | 2024 | 223009 | 0.270 |
Why?
|
Aged | 78 | 2024 | 171117 | 0.270 |
Why?
|
Protein Kinase Inhibitors | 2 | 2024 | 5696 | 0.260 |
Why?
|
Mixed Tumor, Mullerian | 1 | 2006 | 55 | 0.260 |
Why?
|
Phosphorylcholine | 1 | 2006 | 151 | 0.260 |
Why?
|
Carcinoma, Endometrioid | 2 | 2021 | 272 | 0.260 |
Why?
|
Muscle Neoplasms | 1 | 2006 | 130 | 0.250 |
Why?
|
Disease-Free Survival | 15 | 2015 | 6832 | 0.250 |
Why?
|
Abdominal Fat | 1 | 2007 | 217 | 0.240 |
Why?
|
Early Detection of Cancer | 1 | 2019 | 3236 | 0.240 |
Why?
|
Pleural Effusion | 2 | 2013 | 346 | 0.230 |
Why?
|
Adult | 76 | 2024 | 223044 | 0.230 |
Why?
|
Combined Modality Therapy | 13 | 2014 | 8529 | 0.230 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2006 | 614 | 0.220 |
Why?
|
Leiomyosarcoma | 2 | 2021 | 423 | 0.220 |
Why?
|
Infusions, Intravenous | 10 | 2011 | 2229 | 0.220 |
Why?
|
Humans | 125 | 2024 | 765968 | 0.220 |
Why?
|
Anthraquinones | 2 | 1993 | 43 | 0.220 |
Why?
|
Cystadenocarcinoma, Papillary | 1 | 2023 | 56 | 0.210 |
Why?
|
Antibiotics, Antineoplastic | 5 | 2000 | 679 | 0.210 |
Why?
|
Guanine | 2 | 2001 | 282 | 0.210 |
Why?
|
Lung Neoplasms | 14 | 2001 | 13451 | 0.210 |
Why?
|
Ovariectomy | 3 | 2014 | 611 | 0.200 |
Why?
|
Immunotherapy | 1 | 2018 | 4752 | 0.200 |
Why?
|
Survival Rate | 18 | 2018 | 12795 | 0.200 |
Why?
|
Galectin 3 | 1 | 2024 | 238 | 0.200 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2024 | 660 | 0.180 |
Why?
|
Sentinel Lymph Node Biopsy | 2 | 2022 | 728 | 0.170 |
Why?
|
Topotecan | 6 | 2013 | 130 | 0.170 |
Why?
|
Cisplatin | 9 | 2013 | 1658 | 0.170 |
Why?
|
Doxorubicin | 3 | 2012 | 2230 | 0.170 |
Why?
|
Interferon-alpha | 4 | 2000 | 910 | 0.170 |
Why?
|
Home Care Services, Hospital-Based | 1 | 2020 | 43 | 0.170 |
Why?
|
Receptors, Growth Factor | 1 | 2001 | 324 | 0.170 |
Why?
|
Phenyl Ethers | 1 | 1999 | 62 | 0.170 |
Why?
|
Deoxycytidine | 4 | 2014 | 889 | 0.160 |
Why?
|
Lymph Nodes | 3 | 2022 | 3454 | 0.160 |
Why?
|
Melanoma | 1 | 2018 | 5719 | 0.160 |
Why?
|
Histamine Antagonists | 1 | 1999 | 93 | 0.160 |
Why?
|
Sarcoma | 2 | 2006 | 1802 | 0.160 |
Why?
|
Medical Oncology | 3 | 2024 | 2339 | 0.160 |
Why?
|
Ifosfamide | 4 | 1998 | 233 | 0.150 |
Why?
|
Blood Proteins | 1 | 2024 | 1188 | 0.150 |
Why?
|
Aged, 80 and over | 22 | 2021 | 59489 | 0.150 |
Why?
|
Organoplatinum Compounds | 4 | 2010 | 404 | 0.150 |
Why?
|
Neoplasms | 8 | 2006 | 22340 | 0.150 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2001 | 639 | 0.150 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2021 | 363 | 0.150 |
Why?
|
Treatment Outcome | 30 | 2020 | 65188 | 0.150 |
Why?
|
Tretinoin | 1 | 2000 | 524 | 0.140 |
Why?
|
Canada | 8 | 2006 | 2119 | 0.140 |
Why?
|
Maximum Tolerated Dose | 2 | 2014 | 898 | 0.140 |
Why?
|
Robotics | 2 | 2015 | 809 | 0.140 |
Why?
|
Depsipeptides | 1 | 1998 | 95 | 0.140 |
Why?
|
Ontario | 1 | 2018 | 402 | 0.140 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2013 | 5337 | 0.140 |
Why?
|
Radiation-Sensitizing Agents | 1 | 1999 | 347 | 0.140 |
Why?
|
Drug Discovery | 1 | 2024 | 1064 | 0.130 |
Why?
|
Survival Analysis | 9 | 2012 | 10070 | 0.130 |
Why?
|
Retrospective Studies | 24 | 2024 | 81514 | 0.130 |
Why?
|
Leiomyoma | 1 | 2021 | 643 | 0.130 |
Why?
|
Genetic Counseling | 1 | 2020 | 634 | 0.130 |
Why?
|
Obesity, Morbid | 1 | 2007 | 1292 | 0.130 |
Why?
|
Aminoquinolines | 1 | 2016 | 102 | 0.130 |
Why?
|
Paget Disease, Extramammary | 1 | 2016 | 52 | 0.130 |
Why?
|
Dose-Response Relationship, Drug | 10 | 2011 | 10729 | 0.130 |
Why?
|
Leukemia, Myeloid | 1 | 1999 | 696 | 0.130 |
Why?
|
Peptides, Cyclic | 1 | 1998 | 390 | 0.120 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 634 | 0.120 |
Why?
|
Laparoscopy | 1 | 2007 | 2039 | 0.120 |
Why?
|
DNA Repair | 1 | 2024 | 2048 | 0.120 |
Why?
|
Statistics as Topic | 1 | 2001 | 2352 | 0.110 |
Why?
|
Precancerous Conditions | 1 | 2021 | 976 | 0.110 |
Why?
|
New York City | 2 | 2006 | 733 | 0.110 |
Why?
|
Vaginal Neoplasms | 1 | 2014 | 104 | 0.110 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2020 | 950 | 0.110 |
Why?
|
Aminoglycosides | 1 | 1994 | 161 | 0.100 |
Why?
|
Social Support | 1 | 2023 | 2192 | 0.100 |
Why?
|
Histone Deacetylase 1 | 1 | 2013 | 132 | 0.100 |
Why?
|
Pyrazoles | 2 | 1993 | 2033 | 0.100 |
Why?
|
Benzhydryl Compounds | 1 | 1999 | 939 | 0.100 |
Why?
|
Agranulocytosis | 3 | 2000 | 99 | 0.100 |
Why?
|
Parity | 1 | 2016 | 931 | 0.100 |
Why?
|
Piperidones | 1 | 2012 | 37 | 0.100 |
Why?
|
BRCA1 Protein | 2 | 2024 | 1153 | 0.100 |
Why?
|
Prognosis | 7 | 2024 | 29922 | 0.100 |
Why?
|
Colostomy | 1 | 2012 | 107 | 0.100 |
Why?
|
Urinary Diversion | 1 | 2012 | 134 | 0.100 |
Why?
|
Perioperative Care | 1 | 2020 | 1055 | 0.100 |
Why?
|
Psychometrics | 1 | 2021 | 3062 | 0.100 |
Why?
|
Immunologic Factors | 1 | 2000 | 1587 | 0.090 |
Why?
|
Reproduction | 1 | 2016 | 641 | 0.090 |
Why?
|
Astrocytoma | 1 | 1996 | 772 | 0.090 |
Why?
|
Carcinoma | 2 | 2001 | 2312 | 0.090 |
Why?
|
Fertility | 1 | 2016 | 768 | 0.090 |
Why?
|
Pentostatin | 2 | 2000 | 26 | 0.090 |
Why?
|
Intraoperative Care | 1 | 2014 | 760 | 0.090 |
Why?
|
Splenectomy | 2 | 2008 | 390 | 0.090 |
Why?
|
Isoxazoles | 3 | 1990 | 234 | 0.090 |
Why?
|
Leukemia, Hairy Cell | 2 | 2000 | 82 | 0.090 |
Why?
|
Neoplasm Invasiveness | 2 | 2016 | 3602 | 0.090 |
Why?
|
Palliative Care | 4 | 2018 | 3645 | 0.080 |
Why?
|
Breast Neoplasms | 5 | 2006 | 21056 | 0.080 |
Why?
|
Documentation | 1 | 2016 | 916 | 0.080 |
Why?
|
Intestinal Obstruction | 1 | 2013 | 432 | 0.080 |
Why?
|
Glutamates | 2 | 2001 | 384 | 0.080 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2023 | 3537 | 0.080 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2013 | 341 | 0.080 |
Why?
|
Injections, Intravenous | 5 | 2006 | 1377 | 0.080 |
Why?
|
Drug Therapy, Combination | 2 | 2014 | 6309 | 0.080 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2016 | 1657 | 0.080 |
Why?
|
Follow-Up Studies | 7 | 2016 | 39193 | 0.080 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2018 | 2054 | 0.080 |
Why?
|
Feasibility Studies | 4 | 2014 | 5302 | 0.080 |
Why?
|
CA-125 Antigen | 2 | 2009 | 283 | 0.080 |
Why?
|
Prospective Studies | 10 | 2023 | 54802 | 0.070 |
Why?
|
STAT3 Transcription Factor | 1 | 2012 | 870 | 0.070 |
Why?
|
Carcinoma, Small Cell | 3 | 1999 | 420 | 0.070 |
Why?
|
Quality of Life | 9 | 2023 | 13462 | 0.070 |
Why?
|
Pancreatic Fistula | 1 | 2008 | 148 | 0.070 |
Why?
|
Etoposide | 3 | 1999 | 636 | 0.070 |
Why?
|
Decompression, Surgical | 1 | 2013 | 603 | 0.070 |
Why?
|
Healthcare Disparities | 1 | 2023 | 3413 | 0.070 |
Why?
|
Kidney Neoplasms | 3 | 2000 | 4274 | 0.070 |
Why?
|
Disease Progression | 6 | 2013 | 13632 | 0.070 |
Why?
|
Pancreatectomy | 2 | 2008 | 820 | 0.070 |
Why?
|
Carcinoma, Renal Cell | 2 | 2000 | 3181 | 0.070 |
Why?
|
Neoplasm Metastasis | 3 | 2006 | 4893 | 0.070 |
Why?
|
Databases, Factual | 3 | 2008 | 8067 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2022 | 4044 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1410 | 0.070 |
Why?
|
Referral and Consultation | 2 | 2020 | 3615 | 0.070 |
Why?
|
Abdominal Neoplasms | 1 | 2008 | 284 | 0.070 |
Why?
|
Omentum | 1 | 2007 | 165 | 0.070 |
Why?
|
Oxazoles | 2 | 1986 | 198 | 0.070 |
Why?
|
Anxiety | 1 | 2021 | 4671 | 0.070 |
Why?
|
Carmustine | 1 | 2006 | 137 | 0.070 |
Why?
|
Male | 31 | 2018 | 363698 | 0.070 |
Why?
|
Remission Induction | 4 | 2000 | 2411 | 0.060 |
Why?
|
Young Adult | 6 | 2021 | 59889 | 0.060 |
Why?
|
Lymphatic Metastasis | 3 | 2022 | 2887 | 0.060 |
Why?
|
Brain Neoplasms | 3 | 1996 | 9071 | 0.060 |
Why?
|
Infusions, Parenteral | 3 | 2006 | 395 | 0.060 |
Why?
|
Nomograms | 1 | 2007 | 235 | 0.060 |
Why?
|
Abdomen | 2 | 2008 | 1134 | 0.060 |
Why?
|
Peritoneum | 1 | 2006 | 224 | 0.060 |
Why?
|
Pain, Postoperative | 1 | 2016 | 1772 | 0.060 |
Why?
|
Proto-Oncogene Proteins | 2 | 2016 | 4520 | 0.060 |
Why?
|
Academies and Institutes | 1 | 2006 | 326 | 0.060 |
Why?
|
Platinum Compounds | 2 | 2009 | 94 | 0.050 |
Why?
|
DNA Damage | 1 | 2013 | 2457 | 0.050 |
Why?
|
Cohort Studies | 6 | 2022 | 41649 | 0.050 |
Why?
|
Postoperative Care | 2 | 2007 | 1470 | 0.050 |
Why?
|
Glioblastoma | 2 | 1996 | 3459 | 0.050 |
Why?
|
Neutropenia | 4 | 2000 | 893 | 0.050 |
Why?
|
Half-Life | 1 | 2004 | 644 | 0.050 |
Why?
|
Drug Evaluation | 6 | 1992 | 641 | 0.050 |
Why?
|
Thionucleotides | 1 | 2003 | 108 | 0.050 |
Why?
|
Rad51 Recombinase | 1 | 2024 | 191 | 0.050 |
Why?
|
Oligodeoxyribonucleotides, Antisense | 1 | 2003 | 57 | 0.050 |
Why?
|
Inpatients | 1 | 2015 | 2564 | 0.050 |
Why?
|
Length of Stay | 2 | 2015 | 6485 | 0.050 |
Why?
|
Prevalence | 1 | 2019 | 15842 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2020 | 6499 | 0.050 |
Why?
|
Medical Records | 1 | 2007 | 1409 | 0.050 |
Why?
|
Nausea | 3 | 2000 | 680 | 0.050 |
Why?
|
Folic Acid Antagonists | 1 | 2001 | 75 | 0.050 |
Why?
|
Galectins | 1 | 2024 | 294 | 0.050 |
Why?
|
Glioma | 1 | 1996 | 3493 | 0.040 |
Why?
|
Soft Tissue Neoplasms | 1 | 1989 | 1165 | 0.040 |
Why?
|
Endometrial Hyperplasia | 1 | 2021 | 101 | 0.040 |
Why?
|
Liposomes | 1 | 2004 | 788 | 0.040 |
Why?
|
Colorectal Neoplasms | 2 | 2006 | 6942 | 0.040 |
Why?
|
Spleen | 1 | 2006 | 2296 | 0.040 |
Why?
|
Area Under Curve | 1 | 2004 | 1638 | 0.040 |
Why?
|
Fever | 2 | 2013 | 1603 | 0.040 |
Why?
|
Amifostine | 1 | 1999 | 39 | 0.040 |
Why?
|
Apoptosis | 2 | 2013 | 9514 | 0.040 |
Why?
|
Analgesics, Opioid | 1 | 2016 | 3835 | 0.040 |
Why?
|
Patient Selection | 2 | 2015 | 4255 | 0.040 |
Why?
|
Pancreas | 1 | 2006 | 1700 | 0.040 |
Why?
|
Radiation-Protective Agents | 1 | 1999 | 87 | 0.040 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2021 | 218 | 0.040 |
Why?
|
Administration, Oral | 2 | 2006 | 4015 | 0.040 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2024 | 604 | 0.040 |
Why?
|
Salvage Therapy | 1 | 2006 | 1272 | 0.040 |
Why?
|
Nitriles | 1 | 2004 | 982 | 0.040 |
Why?
|
Structure-Activity Relationship | 1 | 2024 | 3051 | 0.040 |
Why?
|
Membrane Proteins | 1 | 2016 | 7851 | 0.040 |
Why?
|
Triazoles | 1 | 2004 | 897 | 0.040 |
Why?
|
Epirubicin | 2 | 2012 | 82 | 0.040 |
Why?
|
United States | 6 | 2023 | 72903 | 0.040 |
Why?
|
Recombinant Proteins | 5 | 2000 | 6493 | 0.040 |
Why?
|
DNA Topoisomerases, Type II | 1 | 1999 | 122 | 0.040 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2017 | 66 | 0.040 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2021 | 388 | 0.040 |
Why?
|
Quality Indicators, Health Care | 1 | 2007 | 1806 | 0.030 |
Why?
|
Cell Line, Tumor | 3 | 2024 | 17075 | 0.030 |
Why?
|
Diphenhydramine | 1 | 1996 | 61 | 0.030 |
Why?
|
Propensity Score | 1 | 2024 | 1968 | 0.030 |
Why?
|
Postoperative Period | 2 | 2013 | 1816 | 0.030 |
Why?
|
Drug Synergism | 1 | 2000 | 1749 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2013 | 9601 | 0.030 |
Why?
|
Fatigue | 2 | 2000 | 1549 | 0.030 |
Why?
|
Risk Factors | 3 | 2019 | 74840 | 0.030 |
Why?
|
Antiemetics | 1 | 1998 | 185 | 0.030 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2024 | 1534 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2013 | 1776 | 0.030 |
Why?
|
Granulocytes | 1 | 1998 | 549 | 0.030 |
Why?
|
Neoplasms, Second Primary | 2 | 2000 | 1050 | 0.030 |
Why?
|
Retroperitoneal Space | 1 | 2016 | 173 | 0.030 |
Why?
|
Paresthesia | 1 | 1996 | 160 | 0.030 |
Why?
|
Carcinoma in Situ | 1 | 2021 | 779 | 0.030 |
Why?
|
Ethics, Medical | 1 | 2001 | 783 | 0.030 |
Why?
|
Rectal Neoplasms | 1 | 1984 | 1182 | 0.030 |
Why?
|
Nephrectomy | 1 | 2000 | 927 | 0.030 |
Why?
|
Hematuria | 1 | 1996 | 230 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2017 | 10383 | 0.030 |
Why?
|
Radiography | 1 | 2006 | 6919 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 1994 | 7478 | 0.030 |
Why?
|
Drug Tolerance | 1 | 1996 | 363 | 0.030 |
Why?
|
Confusion | 1 | 1996 | 277 | 0.030 |
Why?
|
Models, Molecular | 1 | 2024 | 5379 | 0.030 |
Why?
|
Liver | 2 | 2008 | 7562 | 0.030 |
Why?
|
Treatment Failure | 1 | 2000 | 2652 | 0.030 |
Why?
|
Risk Assessment | 1 | 2016 | 24282 | 0.030 |
Why?
|
Administration, Topical | 1 | 2016 | 704 | 0.030 |
Why?
|
Diarrhea | 1 | 2000 | 1316 | 0.030 |
Why?
|
Pregnancy | 1 | 2016 | 30260 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2010 | 22223 | 0.030 |
Why?
|
Clinical Trials as Topic | 3 | 2005 | 8041 | 0.030 |
Why?
|
Cell Proliferation | 2 | 2024 | 10429 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2017 | 878 | 0.030 |
Why?
|
Thoracostomy | 1 | 2013 | 78 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2001 | 1624 | 0.030 |
Why?
|
Extracellular Matrix | 1 | 2001 | 1727 | 0.030 |
Why?
|
Cyclic S-Oxides | 1 | 2012 | 23 | 0.030 |
Why?
|
Arthralgia | 1 | 1996 | 459 | 0.030 |
Why?
|
Hematologic Tests | 1 | 1993 | 239 | 0.030 |
Why?
|
Colonic Neoplasms | 1 | 1984 | 2531 | 0.030 |
Why?
|
Isotretinoin | 1 | 1994 | 135 | 0.020 |
Why?
|
Muscular Diseases | 1 | 1996 | 550 | 0.020 |
Why?
|
Forecasting | 2 | 2005 | 2936 | 0.020 |
Why?
|
Interleukin-3 | 1 | 1993 | 423 | 0.020 |
Why?
|
Cell Movement | 1 | 2024 | 5194 | 0.020 |
Why?
|
Postoperative Complications | 3 | 2016 | 15747 | 0.020 |
Why?
|
Parenteral Nutrition, Total | 1 | 2013 | 304 | 0.020 |
Why?
|
Chemokines | 1 | 2016 | 956 | 0.020 |
Why?
|
Ribavirin | 1 | 1993 | 395 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2001 | 2686 | 0.020 |
Why?
|
Adjuvants, Immunologic | 1 | 2016 | 995 | 0.020 |
Why?
|
Age Factors | 1 | 2007 | 18380 | 0.020 |
Why?
|
Cyclin D1 | 1 | 2012 | 449 | 0.020 |
Why?
|
Cyclophosphamide | 2 | 2013 | 2228 | 0.020 |
Why?
|
DNA | 1 | 2024 | 7202 | 0.020 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 1994 | 647 | 0.020 |
Why?
|
Urinary Tract | 1 | 2013 | 305 | 0.020 |
Why?
|
Government Agencies | 1 | 1990 | 161 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2012 | 2453 | 0.020 |
Why?
|
Drug Design | 1 | 2015 | 1042 | 0.020 |
Why?
|
Sulfonylurea Compounds | 1 | 1992 | 221 | 0.020 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2012 | 720 | 0.020 |
Why?
|
Pilot Projects | 2 | 2016 | 8733 | 0.020 |
Why?
|
Disease Management | 1 | 2020 | 2535 | 0.020 |
Why?
|
Hematologic Diseases | 3 | 1996 | 500 | 0.020 |
Why?
|
Dexamethasone | 1 | 1996 | 1963 | 0.020 |
Why?
|
Drug Hypersensitivity | 1 | 1998 | 902 | 0.020 |
Why?
|
Bone Marrow | 1 | 1999 | 2921 | 0.020 |
Why?
|
Amylases | 1 | 2008 | 171 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8875 | 0.020 |
Why?
|
Pain | 2 | 2000 | 5077 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 4562 | 0.020 |
Why?
|
Peritoneal Cavity | 1 | 2008 | 133 | 0.020 |
Why?
|
Genomics | 1 | 2024 | 5929 | 0.020 |
Why?
|
Blotting, Western | 1 | 2016 | 5020 | 0.020 |
Why?
|
Acute Disease | 1 | 1999 | 7232 | 0.020 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1991 | 891 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2016 | 6113 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2022 | 12509 | 0.020 |
Why?
|
Incidence | 1 | 2006 | 21480 | 0.020 |
Why?
|
BRCA2 Protein | 1 | 2012 | 800 | 0.020 |
Why?
|
Oncology Service, Hospital | 1 | 2007 | 55 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2000 | 4209 | 0.020 |
Why?
|
Time Factors | 2 | 2009 | 40065 | 0.020 |
Why?
|
Ascites | 1 | 2008 | 336 | 0.020 |
Why?
|
Vomiting | 2 | 2000 | 647 | 0.020 |
Why?
|
Outpatients | 1 | 2015 | 1595 | 0.020 |
Why?
|
Down-Regulation | 1 | 2013 | 2927 | 0.020 |
Why?
|
Second-Look Surgery | 1 | 2006 | 27 | 0.020 |
Why?
|
Polyethylene Glycols | 1 | 2012 | 1188 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 12976 | 0.020 |
Why?
|
Transfection | 1 | 2013 | 5743 | 0.020 |
Why?
|
Animals | 3 | 2024 | 168764 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2016 | 2900 | 0.020 |
Why?
|
Adenocarcinoma | 2 | 2017 | 6364 | 0.010 |
Why?
|
Research Design | 1 | 2001 | 6209 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2015 | 2631 | 0.010 |
Why?
|
HEK293 Cells | 1 | 2013 | 4260 | 0.010 |
Why?
|
Protein Processing, Post-Translational | 1 | 2012 | 1957 | 0.010 |
Why?
|
Reactive Oxygen Species | 1 | 2012 | 2140 | 0.010 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2013 | 2024 | 0.010 |
Why?
|
Genes, bcl-2 | 1 | 2004 | 119 | 0.010 |
Why?
|
Epithelial Cells | 2 | 2006 | 3681 | 0.010 |
Why?
|
Genes, erbB-2 | 1 | 2004 | 160 | 0.010 |
Why?
|
Multicenter Studies as Topic | 1 | 2008 | 1731 | 0.010 |
Why?
|
Risk Adjustment | 1 | 2007 | 596 | 0.010 |
Why?
|
Antibodies, Monoclonal | 2 | 2011 | 9249 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2016 | 3475 | 0.010 |
Why?
|
Histones | 1 | 2013 | 2584 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2013 | 2699 | 0.010 |
Why?
|
Drainage | 1 | 2008 | 1179 | 0.010 |
Why?
|
Thrombocytopenia | 1 | 1990 | 1171 | 0.010 |
Why?
|
Cell Survival | 1 | 2012 | 5747 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2013 | 5786 | 0.010 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2004 | 416 | 0.010 |
Why?
|
Patient Compliance | 1 | 2012 | 2692 | 0.010 |
Why?
|
Physical Examination | 1 | 2007 | 1266 | 0.010 |
Why?
|
Phosphorylation | 1 | 2012 | 8278 | 0.010 |
Why?
|
Brachytherapy | 1 | 2008 | 1222 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2016 | 12768 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 1992 | 4348 | 0.010 |
Why?
|
Cladribine | 1 | 2000 | 34 | 0.010 |
Why?
|
Central Nervous System Diseases | 1 | 1984 | 518 | 0.010 |
Why?
|
Medication Adherence | 1 | 2012 | 2192 | 0.010 |
Why?
|
Platelet Count | 2 | 1993 | 782 | 0.010 |
Why?
|
Patient Readmission | 1 | 2013 | 3286 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 3 | 2013 | 20659 | 0.010 |
Why?
|
Survivors | 1 | 2009 | 2372 | 0.010 |
Why?
|
PTEN Phosphohydrolase | 1 | 2004 | 1119 | 0.010 |
Why?
|
Adolescent | 3 | 1998 | 88835 | 0.010 |
Why?
|
Models, Biological | 1 | 1993 | 9443 | 0.010 |
Why?
|
Body Mass Index | 1 | 2015 | 13039 | 0.010 |
Why?
|
Mice | 1 | 2024 | 81819 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2013 | 6547 | 0.010 |
Why?
|
Cough | 1 | 2000 | 597 | 0.010 |
Why?
|
Epithelium | 1 | 2000 | 1599 | 0.010 |
Why?
|
Lymphopenia | 1 | 1997 | 297 | 0.010 |
Why?
|
Postmenopause | 1 | 2004 | 2515 | 0.010 |
Why?
|
Alopecia | 1 | 1999 | 414 | 0.010 |
Why?
|
Kidney | 1 | 1990 | 7066 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 1 | 2004 | 2796 | 0.010 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2004 | 2942 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2021 | 36532 | 0.010 |
Why?
|
Mood Disorders | 1 | 2000 | 1128 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2009 | 15398 | 0.010 |
Why?
|
Dyspnea | 1 | 2000 | 1352 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2007 | 4300 | 0.010 |
Why?
|
Premedication | 1 | 1993 | 244 | 0.010 |
Why?
|
Platinum | 1 | 1993 | 218 | 0.010 |
Why?
|
Neutrophils | 2 | 1993 | 3776 | 0.010 |
Why?
|
Cause of Death | 1 | 2000 | 3708 | 0.010 |
Why?
|
Leukopenia | 1 | 1988 | 213 | 0.000 |
Why?
|
Leukocyte Count | 1 | 1991 | 1602 | 0.000 |
Why?
|
Longitudinal Studies | 1 | 2000 | 14751 | 0.000 |
Why?
|
Heart Rate | 1 | 1993 | 4204 | 0.000 |
Why?
|
Blood Pressure | 1 | 1993 | 8532 | 0.000 |
Why?
|
Cognition Disorders | 1 | 1986 | 3967 | 0.000 |
Why?
|